SEC Form DEFA14A filed by Envoy Medical Inc.

CONTROL ID:

REQUEST ID:

ENVOY MEDICAL, INC

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS
for the Annual Meeting of Stockholders

DATE:

Tuesday, May 12, 2026

TIME:

3:00 PM Central Time

LOCATION:

60 South Sixth Street, Suite 1500, Minneapolis, MN 55402

HOW TO REQUEST PAPER COPIES OF OUR MATERIALS

PHONE: 
Call toll free 
1-866-752-8683

FAX: 
Send this card to 
202-521-3464

INTERNET:
https://www.iproxydirect.com/Coch
and follow the on-screen
instructions.

EMAIL:
Proxy-ID@equinity.com
Include your Control ID in your
email.

This communication represents a notice to access a more complete set of proxy materials available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement is available at: https://www.iproxydirect.com/COCH

If you want to receive a paper copy of the proxy materials you must request one. There is no charge to you for requesting a copy. To facilitate timely delivery please make the request, as instructed above, before April 28, 2026

you may enter your voting instructions at https://www.iproxydirect.com/COCH
until 11:59 pm eastern time May 11, 2026.

The purposes of this meeting are as follows:

1.     To elect two Class III director nominees named in the Proxy Statement to the Envoy Medical Board of Directors, to serve a term that continues until the 2029 annual meeting of stockholders;

2.     To ratify the appointment of EisnerAmper LLP as Envoy Medical’s independent registered public accounting firm for the year ending December 31, 2026;

3.     To approve, on an advisory basis, the Company’s named executive officer (NEO) compensation;

4.     To approve an amendment to the Envoy Medical, Inc. 2023 Equity Incentive Plan;

5.     To approve an amendment to the Envoy Medical, Inc. 2023 Employee Stock Purchase Plan;

6.     To approve, for the purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of warrants to purchase shares of the Company’s Class A Common Stock, par value $0.0001 (“Class A Common Stock”), and the issuance of Class A Common Stck underlying such warrants, that were issued in a transaction that was completed on February 12, 2026; and

7.     To transact any other business as may properly come before the meeting or any adjournments thereof, including matters incident to the conduct of the meeting.